Ewa Jaźwińska−Tarnawska

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment

Ewa Jaźwińska−Tarnawska, K Orzechowska-Juzwenko, P Niewiński et al. · International Journal of Clinical Pharmacology and Therapeutics · 2001 · 35 citations

The impact of liposomes on transdermal permeation of naproxen--in vitro studies.

Dorota Szura, Łukasz Ozimek, Magdalena Przybyło et al. · PubMed · 2014 · 15 citations

Lipid Preparation, Nanomedicine, Naproxen Permeation +14

The influence of locally implanted high doses of gentamicin on hearing and renal function of newborns treated for acute hematogenous osteomyelitis

Mojca Kerec Kos, Ewa Jaźwińska−Tarnawska, Magdalena Hurkacz et al. · International Journal of Clinical Pharmacology and Therapeutics · 2003 · 14 citations